The utility of collagen VII topical gene therapy in the treatment of surgical defect after excision of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma

This case report describes the use of beremagene geperpavec (B-VEC), the first FDA-approved topical gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), in the treatment of a large surgical defect following excision of a squamous cell carcinoma in a 55-year-old patient with RDEB. After wide local excision, the wound was treated with B-VEC, resulting in complete healing within 7 weeks, with no complications or recurrence at the 10-month follow-up. This novel approach highlights the potential of B-VEC to improve surgical outcomes and wound healing in patients with RDEB.